Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Cell‐Free DNA Screening Assay Validated for Trisomies

By LabMedica International staff writers
Posted on 10 Sep 2019
Prenatal screening for trisomies 21, 18, and 13 is currently performed using multiple maternal serum and ultrasound markers. More...
Clinical implementation studies of maternal plasma cell‐free (cf)-DNA testing have demonstrated a much higher sensitivity and specificity for these trisomies.

However, where cfDNA screening has been adopted in public health programs, it is mostly as a second‐tier test. Health economic analyses have identified the necessity of more cost‐effective cfDNA tests to enable a wide adoption of first‐line screening. Targeted tests are based on high complexity genetic analysis platforms that require a relatively advanced laboratory setup.

An international collaboration of scientists led by those at Vanadis Diagnostics (PerkinElmer, Sollentuna, Sweden) analyzed maternal plasma samples from 1,200 singleton pregnancies, which included 158 fetal aneuploidies. Reference outcomes were determined by amniocentesis or chorionic villi sampling (CVS), followed by cytogenetic testing, such as karyotyping, fluorescence in situ hybridization (FISH) or quantitative fluorescence-polymerase chain reaction (QF‐PCR) or clinical examination of neonates.

Processing and analysis of plasma samples was performed using the Vanadis noninvasive prenatal testing (NIPT) was performed blinded to the reference outcomes. The automated Vanadis NIPT assay targets specific chromosomes based on digital molecular quantification in a 96‐well microplate format. The assay enables automated high precision cfDNA analysis from primary blood tubes. The Vanadis NIPT assay relies on a series of enzymatic steps that specifically generate labeled rolling circle replication products (RCPs) from chromosomal cfDNA targets.

The scientists reported that the assay sensitivity was 100% (112/112) for trisomy 21 (Down syndrome), 89% (32/36) for trisomy 18 (Edwards syndrome), and 100% (10/10) for trisomy 13 (Patau syndrome). The respective specificities were 100%, 99.5%, and 99.9%. There were five first pass failures (0.4%), all in unaffected pregnancies. Sex classification was performed on 979 of the samples and 99.6% (975/979) provided a concordant result.

Masoud Toloue, PhD, vice president and general manager of Diagnostics at PerkinElmer, the parent company of Vanadis, said, “We continue to be encouraged by clinical studies that further validate our Vanadis platform as a reliable, cost-effective solution for laboratories and obstetricians to offer aneuploidy screening. Our Vanadis platform eliminates the technical complexity of NIPT, giving more women access to cfDNA screening for common trisomies and further improving prenatal care on a global scale.”

The authors concluded that the study demonstrated that cfDNA testing with the highly automated Vanadis NIPT system does not require specialized personnel for screening. The Vanadis system is also designed to help reduce cost and allow wider population-based screening. The study was published on August 19, 2019, in the journal Prenatal Diagnosis.

Related Links:
Vanadis Diagnostics


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.